XML 57 R48.htm IDEA: XBRL DOCUMENT
v3.22.1

Financial Instruments and Fair Value Measurements - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2022 | Dec. 31, 2021
ISP Fund LP |  |  |  |
Assets |  |  |  |
Lock-up period | 36 months |  | 36 months |
Contributed to partnership for investing | $ 300,000 |  |  |
Cash | ISP Fund LP |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 110,300 |  |  |
Money market funds | ISP Fund LP |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 25,200 |  | $ 3,500 |
Equity investment | ISP Fund LP |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 172,100 |  | 192,200 |
Private Placement Positions | ISP Fund LP |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 2,100 |  |  |
Recurring basis |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 614,868 |  | 606,792 |
Recurring basis | Money market funds |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 103,181 |  | 145,132 |
Recurring basis | Equity investments and money market funds | ISP Fund LP |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 307,576 | [1] | 195,745 | [2]
Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 531,322 |  | 489,704 |
Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Money market funds |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 103,181 |  | 145,132 |
Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Equity investments and money market funds | ISP Fund LP |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 305,516 | [1] | 193,677 | [2]
Recurring basis | Significant Other Observable Inputs, Level 2 |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 64,894 |  | 99,509 |
Recurring basis | Significant Unobservable Inputs, Level 3 |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 18,652 |  | 17,579 |
Recurring basis | Significant Unobservable Inputs, Level 3 | Equity investments and money market funds | ISP Fund LP |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 2,060 | [1] | 2,068 | [2]
Nonrecurring basis | Debt |  |  |  |
Fair Value Measurements |  |  |  |
2023 Notes | 106,499 |  | 261,769 |
2025 Notes | 253,497 |  | 234,498 |
2028 Notes | 260,815 |  |  |
Total fair value of debt | 620,811 |  | 496,267 |
Nonrecurring basis | Significant Other Observable Inputs, Level 2 | Debt |  |  |  |
Fair Value Measurements |  |  |  |
2023 Notes | 106,499 |  | 261,769 |
2025 Notes | 253,497 |  | 234,498 |
2028 Notes | 260,815 |  |  |
Total fair value of debt | 620,811 |  | 496,267 |
Armata | Recurring basis | Equity investment | Common stock |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 122,625 |  | 88,101 |
Armata | Recurring basis | Equity investment | Warrants |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 64,894 |  | 58,595 |
Armata | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Equity investment | Common stock |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 122,625 |  | 88,101 |
Armata | Recurring basis | Significant Other Observable Inputs, Level 2 | Equity investment | Warrants |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 64,894 |  | 58,595 |
Entasis Therapeutics Holdings Inc | Recurring basis | Equity investment | Common stock |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value |  |  | 62,794 |
Entasis Therapeutics Holdings Inc | Recurring basis | Equity investment | Warrants |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value |  |  | 40,914 |
Entasis Therapeutics Holdings Inc | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Equity investment | Common stock |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value |  |  | 62,794 |
Entasis Therapeutics Holdings Inc | Recurring basis | Significant Other Observable Inputs, Level 2 | Equity investment | Warrants |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value |  |  | 40,914 |
InCarda | Recurring basis | Convertible Debt Member |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 652 |  |  |
InCarda | Recurring basis | Equity investment | Warrants |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 1,040 |  | 411 |
InCarda | Recurring basis | Significant Unobservable Inputs, Level 3 | Convertible Debt Member |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 652 |  |  |
InCarda | Recurring basis | Significant Unobservable Inputs, Level 3 | Equity investment | Warrants |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 1,040 |  | 411 |
Gate Neuroscience Member | Recurring basis | Convertible Debt Member |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | 14,900 |  | 15,100 |
Gate Neuroscience Member | Recurring basis | Significant Unobservable Inputs, Level 3 | Convertible Debt Member |  |  |  |
Assets |  |  |  |
Total assets measured at estimated fair value | $ 14,900 |  | $ 15,100 |
[1] | The investments held by ISP Fund LP, consisted of $172.1 million in equity investments, which included $2.1 million in a private placement position, $25.2 million in money market funds and $110.3 million in cash. Our total capital contribution of $300.0 million is subject to a 36-month lock-up period from the date of such capital contributions.
[2] | The investments held by ISP Fund LP, consisted of $192.2 million equity investments and $3.5 million money market funds, are subject to a 36-month lock-up period from our initial contribution date, December 11, 2020.

X
- Definition Fair value portion of long-term notes which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. Senior debt has the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment. + References No definition available. + Details
Name: | inva_ConvertibleSeniorDebtFairValueDisclosures
Namespace Prefix: | inva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value portion of subordinated debt obligations which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. + References No definition available. + Details
Name: | inva_ConvertibleSubordinatedDebtFairValueDisclosures
Namespace Prefix: | inva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The period of time in which contributors to an investment fund have waived the right of redemption, as defined in the partnership agreement. + References No definition available. + Details
Name: | inva_PartnershipAgreementLockUpPeriod
Namespace Prefix: | inva_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258 + Details
Name: | us-gaap_AssetsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_AssetsFairValueDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. + References No definition available. + Details
Name: | us-gaap_ConvertibleDebtFairValueDisclosures
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 55 -Paragraph 69C -URI http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 55 -Paragraph 69B -URI http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1D -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611 + Details
Name: | us-gaap_DebtInstrumentFairValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of capital contributed by the limited partners. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 5 -Subparagraph (SAB TOPIC 4.F) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770 + Details
Name: | us-gaap_LimitedPartnersContributedCapital
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=inva_IspFundLpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=inva_PrivatePlacementPositionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=inva_EquityInvestmentsAndMoneyMarketFundsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_DebtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=inva_IncardaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=inva_GateNeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |